English

Furiex Pharmaceuticals, Inc.

EDGAR

Quarterly report (10-Q) · filed 2014-05-09

18 filing records in this dataset, filed from 2010-08-12 to 2014-05-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

6.42 million USD

2014 Q1 · USD

Exact inputs and evidence

Revenue: 6422000 USD Source

Operating margin

-177.81%

2014 Q1 · %

Exact inputs and evidence

Operating Income: -11419000 USD Source
Revenue: 6422000 USD Source

Operating cash flow

-9.17 million USD

2014 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -9166000 USD Source

Cash and cash equivalents: 22.9 million USD 2014-03-31 Source
Exact value

22902000 USD
Long-term debt including current maturities: 40 million USD 2012-12-31 Source
Exact value

40000000 USD
Shares outstanding: 10.8 million shares 2014-03-31 Source
Exact value

10805611 shares

Reported share-count change

6.84% · 692 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

10114029 shares · 2013-03-31· Source
10805611 shares · 2014-03-31· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2014-05-09.

Financial data available through: 2013-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2013-12-31
Operating income: 4 of 11 periods available· newest 2013-12-31
Net income: 4 of 11 periods available· newest 2013-12-31
Operating cash flow: 4 of 11 periods available· newest 2013-12-31
Capital expenditure: 4 of 11 periods available· newest 2013-12-31
Total assets: 4 of 11 periods available· newest 2013-12-31
Total liabilities: 4 of 11 periods available· newest 2013-12-31
Current assets: 4 of 11 periods available· newest 2013-12-31
Current liabilities: 4 of 11 periods available· newest 2013-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2013-12-31
Long-term debt including current maturities: 2 of 11 periods available· newest 2012-12-31
Shares outstanding: 3 of 11 periods available· newest 2013-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+75.3%

Prior period

USD 40.51 million

2012-01-01 – 2012-12-31
Current period

USD 71 million

2013-01-01 – 2013-12-31

Exact inputs and evidence

70999000 − 40508000 = 30491000 USD

40508000 USD · 2012-01-01 – 2012-12-31
Inspect prior input Prior source
70999000 USD · 2013-01-01 – 2013-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Furiex Pharmaceuticals, Inc. · 2013-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Year-over-year change in Revenue: 30491000 USD Concept: fundies:Revenue Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 70999000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#77388 Filing: 000143774914004302 Input fundies:Revenue: 40508000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#77226 Filing: 000143774914004302
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 13.19 million

Prior period

−USD 42.87 million

2012-01-01 – 2012-12-31
Current period

−USD 29.67 million

2013-01-01 – 2013-12-31

Exact inputs and evidence

-29673000 − -42865000 = 13192000 USD

-42865000 USD · 2012-01-01 – 2012-12-31
Inspect prior input Prior source
-29673000 USD · 2013-01-01 – 2013-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Furiex Pharmaceuticals, Inc. · 2013-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Year-over-year change in Net income: 13192000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -29673000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#82307 Filing: 000143774914004302 Input fundies:NetIncome: -42865000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#82180 Filing: 000143774914004302
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 17.49 million

Prior period

−USD 40.63 million

2012-01-01 – 2012-12-31
Current period

−USD 23.14 million

2013-01-01 – 2013-12-31

Exact inputs and evidence

-23139000 − -40633000 = 17494000 USD

-40633000 USD · 2012-01-01 – 2012-12-31
Inspect prior input Prior source
-23139000 USD · 2013-01-01 – 2013-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Furiex Pharmaceuticals, Inc. · 2013-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Year-over-year change in Operating cash flow: 17494000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -23139000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#103117 Filing: 000143774914004302 Input fundies:OperatingCashFlow: -40633000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#102932 Filing: 000143774914004302
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-66.2%

Prior period

USD 77,000

2012-01-01 – 2012-12-31
Current period

USD 26,000

2013-01-01 – 2013-12-31

Exact inputs and evidence

26000 − 77000 = -51000 USD

77000 USD · 2012-01-01 – 2012-12-31
Inspect prior input Prior source
26000 USD · 2013-01-01 – 2013-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Furiex Pharmaceuticals, Inc. · 2013-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Year-over-year change in Capital expenditure: -51000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 26000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#103664 Filing: 000143774914004302 Input fundies:CapitalExpenditure: 77000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#103483 Filing: 000143774914004302
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2013 2013-01-01 – 2013-12-31

Revenue USD 71 million 100% of revenue
Operating costs Derived USD 95.44 million 134% of revenue
Operating income −USD 24.44 million −34% of revenue
Tax, interest and other Derived USD 5.24 million 7.4% of revenue
Net income −USD 29.67 million −42% of revenue

Cash

Operating cash flow −USD 23.14 million −33% of revenue
Capital expenditure USD 26,000 0% of revenue
Free cash flow Derived −USD 23.17 million −33% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2010 Operating loss: operating costs were 651% of revenue.
2011 Operating loss: operating costs were 1,181% of revenue.
2012 Operating loss: operating costs were 200% of revenue.
2013 Operating loss: operating costs were 134% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2010 2010-01-01 – 2010-12-31	8983000	58504000 Derived	-49521000	5138000 Derived	-54659000	-44007000 Derived	Source 2010-01-01 – 2010-12-31: 8983000 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: -49521000 USD Inspect Operating Income Open source 2010-01-01 – 2010-12-31: -54659000 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: -43324000 USD Inspect Operating Cash Flow Open source 2010-01-01 – 2010-12-31: 683000 USD Inspect Capital Expenditure Open source
2011 2011-01-01 – 2011-12-31	4490000	53046000 Derived	-48556000	425000 Derived	-48981000	-49022000 Derived	Source 2011-01-01 – 2011-12-31: 4490000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: -48556000 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: -48981000 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: -49000000 USD Inspect Operating Cash Flow Open source 2011-01-01 – 2011-12-31: 22000 USD Inspect Capital Expenditure Open source
2012 2012-01-01 – 2012-12-31	40508000	80852000 Derived	-40344000	2521000 Derived	-42865000	-40710000 Derived	Source 2012-01-01 – 2012-12-31: 40508000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -40344000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -42865000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -40633000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 77000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	70999000	95437000 Derived	-24438000	5235000 Derived	-29673000	-23165000 Derived	Source 2013-01-01 – 2013-12-31: 70999000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -24438000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -29673000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -23139000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 26000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 71M 2013

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Revenue	8983000	Revenue: 8983000 Open source
20112011-12-31	Revenue	4490000	Revenue: 4490000 Open source
20122012-12-31	Revenue	40508000	Revenue: 40508000 Open source
20132013-12-31	Revenue	70999000	Revenue: 70999000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

75.3% 2013

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Year over year	No prior comparable period	Revenue: 8983000 Open source
20112011-12-31	Year over year	-50%	Revenue: 4490000 Open source Revenue: 8983000 Open source
20122012-12-31	Year over year	802.2%	Revenue: 40508000 Open source Revenue: 4490000 Open source
20132013-12-31	Year over year	75.3%	Revenue: 70999000 Open source Revenue: 40508000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -34.4% 2013

Net margin -41.8% 2013

Free cash flow margin -32.6% 2013

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Operating margin	-551.3%	Operating Income: -49521000 Open source Revenue: 8983000 Open source
20112011-12-31	Operating margin	-1,081.4%	Operating Income: -48556000 Open source Revenue: 4490000 Open source
20122012-12-31	Operating margin	-99.6%	Operating Income: -40344000 Open source Revenue: 40508000 Open source
20132013-12-31	Operating margin	-34.4%	Operating Income: -24438000 Open source Revenue: 70999000 Open source
20102010-12-31	Net margin	-608.5%	Net Income: -54659000 Open source Revenue: 8983000 Open source
20112011-12-31	Net margin	-1,090.9%	Net Income: -48981000 Open source Revenue: 4490000 Open source
20122012-12-31	Net margin	-105.8%	Net Income: -42865000 Open source Revenue: 40508000 Open source
20132013-12-31	Net margin	-41.8%	Net Income: -29673000 Open source Revenue: 70999000 Open source
20102010-12-31	Free cash flow margin	-489.9%	Revenue: 8983000 Open source Operating Cash Flow: -43324000 Open source Capital Expenditure: 683000 Open source
20112011-12-31	Free cash flow margin	-1,091.8%	Revenue: 4490000 Open source Operating Cash Flow: -49000000 Open source Capital Expenditure: 22000 Open source
20122012-12-31	Free cash flow margin	-100.5%	Revenue: 40508000 Open source Operating Cash Flow: -40633000 Open source Capital Expenditure: 77000 Open source
20132013-12-31	Free cash flow margin	-32.6%	Revenue: 70999000 Open source Operating Cash Flow: -23139000 Open source Capital Expenditure: 26000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -23.1M 2013

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Operating cash flow	-43324000	Operating Cash Flow: -43324000 Open source
20112011-12-31	Operating cash flow	-49000000	Operating Cash Flow: -49000000 Open source
20122012-12-31	Operating cash flow	-40633000	Operating Cash Flow: -40633000 Open source
20132013-12-31	Operating cash flow	-23139000	Operating Cash Flow: -23139000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -23.2M 2013

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Free cash flow	-44007000	Operating Cash Flow: -43324000 Open source Capital Expenditure: 683000 Open source
20112011-12-31	Free cash flow	-49022000	Operating Cash Flow: -49000000 Open source Capital Expenditure: 22000 Open source
20122012-12-31	Free cash flow	-40710000	Operating Cash Flow: -40633000 Open source Capital Expenditure: 77000 Open source
20132013-12-31	Free cash flow	-23165000	Operating Cash Flow: -23139000 Open source Capital Expenditure: 26000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

79.1% 2013

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2010-12-31	Liabilities / assets	Not reported	No source recorded
20112011-12-31	Liabilities / assets	21.9%	Total Liabilities: 20801000 Open source Total Assets: 95124000 Open source
20122012-12-31	Liabilities / assets	60.3%	Total Liabilities: 57158000 Open source Total Assets: 94755000 Open source
20132013-12-31	Liabilities / assets	79.1%	Total Liabilities: 70001000 Open source Total Assets: 88442000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.64× 2013

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2010-12-31	Current assets / current liabilities	Not reported	No source recorded
20112011-12-31	Current assets / current liabilities	3.84×	Current Assets: 45827000 Open source Current Liabilities: 11920000 Open source
20122012-12-31	Current assets / current liabilities	1.7×	Current Assets: 37783000 Open source Current Liabilities: 22239000 Open source
20132013-12-31	Current assets / current liabilities	1.64×	Current Assets: 37746000 Open source Current Liabilities: 22954000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2010 2010-01-01 – 2010-12-31	−USD 54.66 million Exact value Exact value: -54659000 USD 2010-01-01 – 2010-12-31: -54659000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Furiex Pharmaceuticals, Inc. · 2010-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Net Income: -54659000 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: -54659000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774913003083/furx-20121231.xml#62814 Filing: 000143774913003083 The citation records this snapshot. The page link may show a newer release later.	−USD 43.32 million Exact value Exact value: -43324000 USD 2010-01-01 – 2010-12-31: -43324000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Furiex Pharmaceuticals, Inc. · 2010-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Operating Cash Flow: -43324000 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -43324000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774913003083/furx-20121231.xml#85801 Filing: 000143774913003083 The citation records this snapshot. The page link may show a newer release later.	USD 683,000 Exact value Exact value: 683000 USD 2010-01-01 – 2010-12-31: 683000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Furiex Pharmaceuticals, Inc. · 2010-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Capital Expenditure: 683000 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478/explain?concept=fundies%3ACapitalExpenditure&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 683000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774913003083/furx-20121231.xml#86356 Filing: 000143774913003083 The citation records this snapshot. The page link may show a newer release later.	−USD 44.01 million Calculation and evidence -43324000 − 683000 USD Exact free cash flow: -44007000 USD 2010-01-01 – 2010-12-31: -43324000 USD · Inspect Operating Cash Flow · Source 2010-01-01 – 2010-12-31: 683000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Furiex Pharmaceuticals, Inc. · 2010-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Free cash flow: -44007000 USD Concept: free-cash-flow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -43324000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774913003083/furx-20121231.xml#85801 Filing: 000143774913003083 Input fundies:CapitalExpenditure: 683000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774913003083/furx-20121231.xml#86356 Filing: 000143774913003083 The citation records this snapshot. The page link may show a newer release later.
2011 2011-01-01 – 2011-12-31	−USD 48.98 million Exact value Exact value: -48981000 USD 2011-01-01 – 2011-12-31: -48981000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Furiex Pharmaceuticals, Inc. · 2011-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Net Income: -48981000 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: -48981000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#82053 Filing: 000143774914004302 The citation records this snapshot. The page link may show a newer release later.	−USD 49 million Exact value Exact value: -49000000 USD 2011-01-01 – 2011-12-31: -49000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Furiex Pharmaceuticals, Inc. · 2011-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Operating Cash Flow: -49000000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -49000000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#102747 Filing: 000143774914004302 The citation records this snapshot. The page link may show a newer release later.	USD 22,000 Exact value Exact value: 22000 USD 2011-01-01 – 2011-12-31: 22000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Furiex Pharmaceuticals, Inc. · 2011-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Capital Expenditure: 22000 USD Concept: fundies:CapitalExpenditure Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478/explain?concept=fundies%3ACapitalExpenditure&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 22000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#103302 Filing: 000143774914004302 The citation records this snapshot. The page link may show a newer release later.	−USD 49.02 million Calculation and evidence -49000000 − 22000 USD Exact free cash flow: -49022000 USD 2011-01-01 – 2011-12-31: -49000000 USD · Inspect Operating Cash Flow · Source 2011-01-01 – 2011-12-31: 22000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Furiex Pharmaceuticals, Inc. · 2011-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Free cash flow: -49022000 USD Concept: free-cash-flow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -49000000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#102747 Filing: 000143774914004302 Input fundies:CapitalExpenditure: 22000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#103302 Filing: 000143774914004302 The citation records this snapshot. The page link may show a newer release later.
2012 2012-01-01 – 2012-12-31	−USD 42.87 million Exact value Exact value: -42865000 USD 2012-01-01 – 2012-12-31: -42865000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Furiex Pharmaceuticals, Inc. · 2012-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Net Income: -42865000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42865000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#82180 Filing: 000143774914004302 The citation records this snapshot. The page link may show a newer release later.	−USD 40.63 million Exact value Exact value: -40633000 USD 2012-01-01 – 2012-12-31: -40633000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Furiex Pharmaceuticals, Inc. · 2012-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Operating Cash Flow: -40633000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -40633000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#102932 Filing: 000143774914004302 The citation records this snapshot. The page link may show a newer release later.	USD 77,000 Exact value Exact value: 77000 USD 2012-01-01 – 2012-12-31: 77000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Furiex Pharmaceuticals, Inc. · 2012-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Capital Expenditure: 77000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 77000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#103483 Filing: 000143774914004302 The citation records this snapshot. The page link may show a newer release later.	−USD 40.71 million Calculation and evidence -40633000 − 77000 USD Exact free cash flow: -40710000 USD 2012-01-01 – 2012-12-31: -40633000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 77000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Furiex Pharmaceuticals, Inc. · 2012-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Free cash flow: -40710000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -40633000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#102932 Filing: 000143774914004302 Input fundies:CapitalExpenditure: 77000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#103483 Filing: 000143774914004302 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 29.67 million Exact value Exact value: -29673000 USD 2013-01-01 – 2013-12-31: -29673000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Furiex Pharmaceuticals, Inc. · 2013-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Net Income: -29673000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29673000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#82307 Filing: 000143774914004302 The citation records this snapshot. The page link may show a newer release later.	−USD 23.14 million Exact value Exact value: -23139000 USD 2013-01-01 – 2013-12-31: -23139000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Furiex Pharmaceuticals, Inc. · 2013-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Operating Cash Flow: -23139000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23139000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#103117 Filing: 000143774914004302 The citation records this snapshot. The page link may show a newer release later.	USD 26,000 Exact value Exact value: 26000 USD 2013-01-01 – 2013-12-31: 26000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Furiex Pharmaceuticals, Inc. · 2013-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Capital Expenditure: 26000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#103664 Filing: 000143774914004302 The citation records this snapshot. The page link may show a newer release later.	−USD 23.17 million Calculation and evidence -23139000 − 26000 USD Exact free cash flow: -23165000 USD 2013-01-01 – 2013-12-31: -23139000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 26000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Furiex Pharmaceuticals, Inc. · 2013-12-31 Furiex Pharmaceuticals, Inc. (edgar:1484478) Free cash flow: -23165000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T19:50:00Z Snapshot: 5f5da76d491b3e8b510323485790a481de69e02f6e1c4f0ce4fcab5f868cbdbd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1484478?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23139000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#103117 Filing: 000143774914004302 Input fundies:CapitalExpenditure: 26000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1484478/000143774914004302/furx-20131231.xml#103664 Filing: 000143774914004302 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

18 filings · 1,082 latest values · 1,082 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001484478, 1484478, edgar:1484478

Also known as Furiex Pharmaceuticals, Inc.

Furiex Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2013 2013-01-01 – 2013-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation